Dan Karelitz is a partner in the firm's Business Law Department and a member of the Tax Group. Mr. Karelitz has strong general tax experience, advising sponsors on fund formation and portfolio company acquisition, disposition, and restructuring matters in the technology, private equity and real estate spaces. In addition, borrowing on deep experience in the private equity and real estate transaction space, and combined with his background as an organic chemist, Mr. Karelitz has a particular focus on the Life Sciences sector advising clients on structuring their operations, strategic transactions, acquisitions and divestitures in a tax-efficient manner.

He joined Goodwin in 2007.

Areas of Practice




Representative Matters

Repräsentative Angelegenheiten


Public Offerings
  • AquaVenture Holdings in its $117 million initial public offering
  • Intellia Therapeutics in its $108 million initial public offering
  • CRISPR Therapeutics in its $56 million initial public offering
Private Financings
  • Moderna Therapeutics in its $110 million Series D financing and $500 million Series E financing
  • Intellia Therapeutics in its $15 million Series A financing and $70 million Series B financing
  • Nimbus Therapeutics in its $43 million Series B financing
  • Scholar Rock in its $36 million Series B financing
Strategic Collaborations and M&A
  • Teva Pharmaceuticals in its $3.2 billion acquisition of Auspex Pharmaceuticals
  • Versant Ventures in its strategic transaction with Bayer to form BlueRock Therapeutics, with a combined financing amount of $225 million
  • Foundation Medicine in its strategic collaboration with Roche, valued at more than $1 billion
  • Quartet Medicine in its $595 million strategic collaboration with Merck
  • Nimbus Therapeutics in its sale to Gilead, with $400 million upfront and the potential to receive an additional $800 million over time
  • CRISPR Therapeutics in its collaboration with Bayer, valued up to $335 million upfront
  • Padlock Therapeutics in its $225 million sale to Bristol Myers Squibb
  • F-star Alpha in its agreement with Bristol-Myers Squibb
  • Moderna Therapeutics in its collaboration with AstraZeneca to co-develop and co-commercialize immune-oncology mRNA Therapeutics. 

In The News

In den Nachrichten






J.D., 2008
Georgetown University

(magna cum laude, Order of the Coif)

M.S., 2004
Emory University
B.S., 2004
Emory University

(Phi Beta Kappa)



Get In Touch
In Kontakt kommen
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.


Search Other Lawyers
Suche Andere Rechtsanwälte